The identification of proteins involved in brain ischemia might allow the discovery of putative biomarkers or therapeutic targets for ischemic stroke. Our aim is to study the distribution of proteins within mouse brain after an ischemic insult using MALDI Imaging-Mass-Spectrometry and to identify relevant proteins involved in brain damage. We occluded the middle cerebral artery of C57BL/6J mice. Brain slices were analyzed by MALDI-TOF and infarct (IC) and contralateral (CL) regions were compared using ClinProTools. The ion distribution maps of relevant m/z values were obtained by FlexImagin3.0. Protein identification was conducted through a bottom-up approach consisting on complementary sample fractionation methods. Some identifications were confirmed by immunohistochemistry and western blot. We identified 102 m/z values with different abundances between IC and CL (p<0.05), from which 21 m/z peaks were selected as more relevant. Thirteen of them were found increased in the infarct region and 4 m/z values showed AUC>90% between IC and CL. Identification analyses confirmed altered expressions of ATP5i, COX6C and UMP-CMP kinase in IC compared to CL.
A C C E P T E D M A N U S C R I P T INTRODUCTION
Ischemic stroke is one of the most important neurological disorders and cause of disability worldwide [1] . Brain ischemia is originated by the impairment of blood supply into the brain parenchyma due to an arterial occlusion. This process encompasses a complex cascade of events that affects both cellular and extracellular matrix components including the inflammatory response, the immune cells extravasation, the development of edema or the blood-brain-barrier disruption [2] . Finally, it leads to cell death and tissue injury which is translated into a loss of neurological functions [3] . The identification of key molecules involved in brain injury and repair would help to design future treatments for neuroprotection and neurorecovery.
There are several experimental models of ischemic stroke developed in different species, especially rodents. The murine model which consists of the transient occlusion of the distal middle cerebral artery exhibits a reproducible cerebral infarct with a controlled reperfusion, low mortality rates and measurable neurological impairment during the acute phase [4, 5] . This model is extremely useful for the study of cerebral ischemia pathophysiology and has been extensively used in the discovery of new molecules involved in brain injury [6] [7] [8] [9] .
MALDI imaging mass spectrometry (MALDI-IMS) is a powerful technique that allows to obtain the profiling of a broad range of molecules [10] such as metabolites [11] [12] [13] [14] [15] [16] , lipids [17] [18] [19] [20] [21] [22] [23] , proteins [24] [25] [26] or drugs [27] [28] [29] [30] [31] directly on tissue [32] . In addition, it permits to analyze their spatial distribution and their local abundance simultaneously.
This innovative technique has been proven to be useful for the molecular diagnostic in the context of inflammatory diseases [33] [34] [35] , traumatic injuries [36, 37] , vascular diseases [17, 38] , neurodegenerative disorders [39] and specially in different types of tumors [40, 41] . MALDI-IMS has been also employed for the study and visualization of lipid distribution in the brain after focal ischemia [42] [43] [44] . However, as far as we know a complete MALDI IMS profiling of proteins in the context of cerebral ischemia has not been yet conducted. The identification of new proteins involved in brain ischemia might allow the discovery of a new set of putative candidates to become biomarkers of A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 4 ischemic stroke and new potential therapeutic targets. This deeper knowledge would permit the study of pathways related with this sever disorder and its progression.
In our study we aim to visualize changes in the brain protein profile in a mouse model of brain ischemia and to identify new putative biomarkers or therapeutic targets by means of MALDI IMS.
METHODS

Animals
Adult male C57BL/6Ncrl mice (body weight from 25 to 30 g) were used for the study. 
Transient middle cerebral artery occlusion (tMCAO)
The surgery was conducted as previously reported [5] . Briefly, mice were anesthetized with isofluorane (4% for induction, 2% for maintenance in air, 79% N 2 : 21% O 2 ; Abbot Laboratories, Madrid, Spain). Buprenorphin (0.05-0.1 mg/kg) was administered subcutaneously as analgesic for post-surgical pain. The distal part of the middle cerebral artery (MCA) was exposed after performing a small craniotomy in the left temporal bone, leaving the dura intact. The MCA was directly compressed for 60 min using a micromanipulator holding a 30G blunted needle decreasing the cerebral blood flow to <25% of the baseline values. After the arterial occlusion, the needle was removed and the cerebral blood flow (CBF) recovered at least the 75% of the baseline.
During the entire procedure the body temperature was maintained at 36.5-37ºC using a heating blanket and controlled by a rectal probe and the CBF was recorded by laser Doppler flowmetry (Moor Instruments, Devon, UK). After 24 hours animals were euthanized under deep anesthesia by cardiac perfusion as it follows: animals used for
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MALDI IMS
Brain tissue processing, MALDI mass spectrometry and image analysis
Brains (n=4) were isolated and immediately snap frozen in isopentane (Sigma, USA) at - After the MS analysis, hematoxylin & eosin (H&E) staining (Sigma) was performed in each brain section and they were used as reference for colocalization to select the regions of interest (ROI).
Data quantification and statistical MALDI-IMS data analysis
After MALDI analysis, we used FlexImaging 3.0 (Bruker Daltonics, Germany) software to obtain ion density maps and to define the ROIs on each brain section. Two ROIs were defined on each brain section based on H&E staining. One ROI was defined on
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ACCEPTED MANUSCRIPT 6 the infarct core (IC) at the cerebral cortex and another ROI on the contralateral healthy (CL) area. In each brain section a dataset file was obtained with the spectra of each pixel contained in the ROIs. Then, all dataset files were combined in a single XML to be statistically analyzed with ClinProTools V3.0 software (Bruker Daltonics, Germany). The analysis of the mass spectra was focused on the mass range 2,000-24,000 m/z. The following settings were used for recalibration: a top hat baseline correction of 10% of minimal baseline width, a maximum peak shift of 2,000 ppm for peak alignment and 20% match to the calibrant peaks. Not recalibratable spectra were excluded from the statistical analysis. Signal to noise ratio for data acquisition was set to 5. An average spectrum from each ROI and the average peak list were obtained. Peak intensities were compared by t-test. In order to check the homogeneity of the spectra set we carried out principal components analysis (PCA) with the Matlab algorithm and used the 3 primary PCAs for the 3-D scaling representation. To select the most relevant m/z peaks from the average peak list we used the loading plot coupled to each PCA graphic. We also obtained the area under the curve (AUC) of each m/z peak to assess the discrimination between contralateral (CL) and infarct (IC) of each m/z peak.
Bottom-up protein identification strategies
We set up two parallel strategies in order to maximize the number of identified proteins with molecular masses matching our relevant m/z obtained from MALDI IMS analysis. A diagram of the followed experimental workflow is shown in figure 1 .
Laser micro-dissection and protein extracts
We mounted consecutive brain cryosections of 12 µm thickness obtained from the 
Tissue homogenates and reverse phase HPLC (RP-HPLC)
For RP-HPLC separations, mechanical homogenates of IC and CL areas of mouse brain were obtained in 0.2% of TFA and 60% of acetonitrile (ACN). Samples were sonicated using the parameters described above. Insoluble material was removed by centrifugation at 13,000 g at 4ºC, protease inhibitors were added into the recovered supernatant and samples were stored at -80 o C until use. Soluble proteins were separated using the Alliance HPLC system (Waters) and a C4 widepore 3.6 µm; 4.6x100 mm Aeris reverse phase (RP) column (Phenomenex). Solvent A was 0.1% TFA in water and solvent B was 0.1% TFA in ACN. A linear gradient from 10 to 30% for 1 min, followed by a second step from 30 to 90% for 60 min was applied. Fractions were collected every 2 min, dried using a SpeedVac (Thermo Scientific) and reconstituted in 30 µL of H 2 O 0.1 % TFA mixed at 1:1 volume ratio with sinapinic acid matrix (10 g/ml, in 1:2 H 2 O:ACN, 0.2 % TFA). Finally samples were mounted onto a ground steel plate, let to crystalize and mass spectra were obtained by MALDI MS analysis (lineal mode, 24kV) to check for the presence of m/z of interest.
Bottom-up nano LC-MS/MS
Tryptic peptides from tricine gel sections and from RP-HPLC fractions of interest were analyzed on a LTQ Velos-Orbitrap mass spectrometer (ThermoFisher Scientific, Bremen, Germany) coupled to a nano-HPLC system (Proxeon Biosystems, Thermo
Fisher Scientific, Bremen)). Briefly, peptide mixtures were initially concentrated on an EASY-column, 2 cm long, 100 μm internal diameter (id), and packed with ReproSil C18, with the masses of proteins and/or peptides retrieved by PeptideMass considering a maximum mass shift of 2,000 ppm, which corresponds to the maximum peak shift allowed in peak alignment during the recalibration of MALDI IMS spectra.
Verification of candidates
Immunohystochemistry
Some of the predicted proteins were selected based on their biological function and the availability of commercial antibodies to be confirmed by immunohistochemistry.
Sections of 12 µm of thickness (+0.5 to +1.9 µm from bregma) were obtained from mouse brains previously fixed with PFA. The brains were cryoprotected with 30% sucrose in PBS, embedded in OCT and kept at -80 o C until use (N=4-5). Brain sections were acetone-fixed and subjected to antigen retrieval in citric acid (pH=6 / 95 o C). 
Results
MALDI IMS
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 11 We obtained the average spectra of the infarct (IC) and the contralateral (CL) healthy areas, and identified a total of 102 m/z values with different intensities between both regions (p<0.0001) (Figure 2A ). PCA analysis revealed a good discrimination between IC and CL when PC1 was combined with PC2 and PC3 ( Figure 2B ). Using loading plot analysis we selected the 21 most-relevant m/z values ( Figure 2B and 2C ) and
subsequently obtained their ion distribution map to visualize their positioning along the whole brain sections. All the m/z peaks colocalized with the injured infarcted area revealing an increase or a decrease in its relative abundance (table 1) .
Four out of the 21 most relevant m/z peaks showed a very high discrimination capacity between IC and CL with AUC>0.9 ( figure 3 ). When other parts of the brain sections were visualized, the peak m/z 6726 was found more abundant in the ventral striatum whereas the peaks m/z 7545 and m/z 4815 were found increased in the cerebral cortex and the region of the pallidum respectively. In contrast, m/z 8458 appeared significantly increased in the IC area when compared with the equivalent region in the CL area and only the anterior commissure retrieved an elevated abundance compared to other parts of the healthy tissue. (Figure 3 ).
Protein identification by Bottom-up approach
We obtained the protein extract of the IC and CL areas from adjacent brain sections by means of laser microdissection and fractionated them through 1D tricine gels. Given that the proteins that were found most relevant in terms of discrimination capacity after MALDI-IMS analysis ranged from 4,285 to 22,178 m/z, the regions of the tricine gels comprised between 4 and 23 KDa were cut and digested with trypsin. After nanoLC-MS/MS analysis we identified a total of 666 proteins with at least 2 unique peptides: 257 were only found in CL, 61 in IC and 348 proteins were identified in homogenates from both regions, CL and IC (Supplemental table S1). After determining the masses of the identified proteins considering all the described PTMs, we matched 8 m/z peaks with the MALDI-IMS results ( Table 2 ).
In a parallel approach we fractionated IC and CL brain homogenates by RP-HPLC using (Figure 4 ).
These fractions were digested using trypsin and then analyzed through nanoLC-MS/MS. As a result a total of 495 proteins were identified with ≥2 unique peptides ( Supplemental table S2 ). Among the identified proteins we found matches for the m/z 5708.072, 8110.95, 8569.93 and 8569.9, all of them previously reported in the MALDI-IMS experiment. The proteins corresponding to these m/z were ATP5e, ATP5i, Nedd8
and ubiquitin, which were identified with a sequence coverage>35% and an identification SCORE>60 (Table 3 ).
Immunohistochemistry
After the immunohistochemistry analysis, the proteins ATP5i and COX6C showed a higher expression in the IC region compared to the CL area (p<0.05 and p<0.2, respectively). In contrast, UMP-CMP kinase showed a significant decrease (p<0.01), confirming the results obtained by MALDI-IMS ( Figure 5A , 5B and 5C).
Western Blot
As expected, western blot analyses in IC and CL regions from brain homogenates showed that, ATP5i expression was increased in IC whereas UMP-CMPK was decreased. In contrast, no differences were found in COX6C expression when both regions were compared.
Discussion
The present study shows for the first time the profiling and spatial distribution of proteins along different regions of mouse brain subjected to focal ischemia using the state of the art technique MALDI IMS.
During the last decade, the identification of the protein identity related to each m/z peak has generally been elusive in studies applying MALDI-IMS, precluding the validation of the results and the elucidation of the biological processes involved.
However, different identification approaches have been developed by MALDI imaging users. Indirect identifications correlating proteomic strategies (i. e. bottom-up) and
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ACCEPTED MANUSCRIPT 13 imaging data represent an effective approach for protein identity verification [47] . An alternative strategy that has been proven successful consist of the comparison of the presence and distribution of the protein of interest between wild type animals and knockout experimental models [48, 49] . Recently, important steps forward were made with the optimization of on-tissue digestion protocols [50] . Following tryptic digestion, protein identification can be reached after the analysis of the generated peptides.
However, low fragmentation efficiencies and high background signal are important challenges to overcome. A significant advancement was achieved in molecular imaging strategies with the use of MALDI FITCR IMS for the analysis of tissue sections [51, 52] .
MALDI FITCR IMS provides the highest mass resolution and accuracy and allows the obtaining of high spatial resolution images. These improvements might facilitate a substantial progress to effectively link proteomic experiments with imaging data in future studies thanks to the application of next generation analytical tools.
In our study, after MALDI IMS analysis, we followed a bottom-up strategy to correlate imaging with proteomic analyses. As a result we identified a total of 21 relevant protein species differently expressed in IC compared to the CL region. We were able to identify different proteins after the development and combination of different sample fractionation methods based on size or hydrophobicity separation. In addition, after the bottom-up analysis we took into account the putative post-translationally modified forms of the identified proteins to become one step closer to the real tissue phenotype, where PTMs and protein processing occur. Following this strategy we identified and confirmed ATP5i, COX6C and UMP-CMP kinase as proteins related to brain ischemia.
During cerebral ischemia the production of cellular energy is impaired and ATP concentration decreases promoting the depolarization of the neuron membranes and causing an imbalance of Na + , K + and Ca 2+ [53] . This alteration of the ion homeostasis induces the release of neurotransmitters, further inhibits the production of ATP and activates endogenous proteases enlarging the cytotoxic response to ischemia. Ischemic injury also increases the amounts of reactive oxygen species (ROS) which attack key cellular components, especially in the reperfused regions [54] . We identified two proteins, ATP5i and COX6C, which are increased in the ischemic tissue when compared
ACCEPTED MANUSCRIPT 14 with the healthy contralateral area of the brain. Both proteins are members of the oxidative phosphorylation pathway (OXPHOS) thus involved in the production of energy in eukaryotic cells resulting from the oxidation of nutrients. ATP5i is the subunit e of the F0 complex, which comprises the proton channel in the ATP synthase complex in the inner membrane of the mitochondria [55] . Our results are in line with others' in which ATP synthase complex 5 together with other mitochondrial proteins has been found increased in the middle cerebral arteries isolated from the ischemic region compared with the healthy area and non-ischemic animals [56] . After MALDI IMS analysis we also found the m/z 5712 increased in IC. This m/z value might correspond to the ATP synthase complex subunit ATP5E although these results could not be replicated by immunohistochemistry. In contrast, ATP5 subunit beta has been found significantly decreased in rat cortical neurons after chemically induced ischemia [57] .
These divergences might reflect the different response to ischemia of the components of the neurovascular unit. Similarly to ATP5i, we found an increased abundance of the Cytochrome c oxigenase (COX) complex subunit COX6C in the IC of the brain compared to the CL area. COX6C is a nuclear-coded polypeptide that is tightly bound to the catalytic subunits I and II [58] and its expression together with other COX subunits has been found altered in neurological diseases such as Alzheimer's [59] . Although no specific function has been yet described for COX6C it may be involved in the regulation and assembly of the complex COX. COX is the last heteromeric complex (complex IV) of the mitochondrial respiratory chain that catalyzes the electron transfer to oxygen. Its inhibition due to the lack of oxygen is a central initial process of the ischemic damage [60] . The increase of ATP5i and COX6C expression found through our analysis by MALDI-IMS might be promoted by the requirement of a greater mitochondrial function to restore oxidative phosphorylation after ischemia. This compensatory effect against the lack of oxygen might be promoted by the increase of total mitochondrial mass after ischemia due to mitochondrial biogenesis [61, 62] . Interestingly, COX activity has been found altered after ischemic stroke in cerebrospinal fluid and erythrocyte hemolysate of patients compared to healthy controls [63] . In other analyses performed in brain tissue, some authors have found increased expression of COX subunit I after global cerebral ischemia [64] . In contrast, others have found a COX subunit I decrease in the region of the infarct core after a tMCAo of 90 min and 48h of reperfusion [65] .
ACCEPTED MANUSCRIPT 15 These controversies may reflect the dependence of the process on the time of ischemia and reperfusion [66] . Deficiencies in COX function, expression or assembly have been related with other diseases such as the mitochondrial disorders Leigh Syndrome [67] , neonatal hypertrophic cardiomyopathy [68] or early-onset leukodystrophic encephalopathy [69] .
The modulation of proteins members of the OXPHOS pathway has been already considered for neuroprotection [70, 71] . Although the strategies of ROS scavenging have resulted futile, the uncoupling of mitochondrial membrane potential through the stimulation of proton channels and the induction of OXPHOS complexes phosphorylation seem promising approaches that may reduce the effects of ischemia [66] . Our results suggest the implication of the subunits ATP5i and COX6C in the brain infarct development, thus presenting them as potential molecules to modulate and minimize neuronal injury.
On the other hand, UMP-CMP kinase acts as an uridylate-cytidylate kinase that catalyzes the phosphorylation of CMP and UMP with the consequent formation of the nucleosides CDP and UDP, which are further phosphorylated to its triphosphate forms at the expense of ATP [72] . These nucleosides are required for the cellular nucleic acid synthesis [73] but they also play important roles in neuronal function. More precisely, they are involved in the regulation of adenylate cyclase and protein synthesis, as well as sugar metabolism, synthesis of phospholipids and release of neurotransmitter [74] .
During brain ischemia, a decrease in the levels of CTP and UTP has been observed [75] , and the exogenous administration of these nucleosides has been proven to be neuroprotective in different models of brain ischemia [74] . A decreased expression of UMP-CMP kinase in the mouse cerebral cortex has been related to aging [76] but, to our knowledge, no study has explored UMP-CMP kinase in brain ischemia. In this regard we found a decreased expression of UMP-CMP kinase in the IC compared to the CL healthy area of mouse brain. This finding suggests that UMP-CMP kinase might play a role in the modulation and promotion of the pyrimidine nucleoside metabolism restoration after ischemia, which could be accompanied by a recovery of the brain function.
ACCEPTED MANUSCRIPT 16 The application of MALDI-imaging allowed us to compare the relative abundance of proteins at different regions of interest and to identify new potential biomarkers of brain ischemia or candidate therapeutic targets for tissue recovery. After the combination of two different identification strategies after bottom-up analysis, four proteins were identified in both approaches.
Our study stands with some limitations. Despite different attempts, we were not able to obtain good quality spectra after on-tissue trypsin digestion (data not shown). The results of this analysis might have permitted the identification of further putative candidates. By the development of the strategies presented in our study we were able to identify different protein candidates, however, apart from COX6C (m/z 8458), we failed to identify other m/z that retrieved a very high discrimination ability between IC and CL (with AUC>0.9). In addition, we were not able to obtain chromatographic fractions highly enriched with proteins of interest in order to perform a top-down approach for protein identification (not shown). The protein identification based on bottom-up analysis is limited by i) the mass error inherent to MALDI-imaging in the analysis of intact proteins, and ii) the presence of PTMs which can difficult the protein mass calculation based on the aminoacid sequence. The mass tolerance considered to link the MALDI IMS data with bottom-up results was 2,000 ppm, a narrow tolerance window similar to other authors' [36, 77, 78] . During this process, all PTMs that are described for each protein were taken into account although protein-m/z matching based on molecular weight is complex especially in the analysis of big biomolecules.
Thus, the presence of false negative and false positive identifications cannot be excluded. In spite of that, we validated some of the candidates by orthogonal methodologies and found patterns of expression which are coherent with MALDI imaging data. Our identification strategy might be improved in near future considering unspecific protein degradation by endogenous proteases.
Future additional studies are needed to confirm our findings. The application of MALDI IMS in other models of brain ischemia and with different times of occlusion might also help in finding proteins involved in the early response to brain ischemia. Future studies will assess the value of the identified proteins as biomarkers in human stroke.
Conclusion
We characterized for the first time the protein profile and distribution of brain subjected to ischemia and we were able to determine changes in protein abundance in a murine model using MALDI imaging MS. Proteomic results were confirmed by immunohistochemistry and western blot in independent samples and the identified candidates might represent putative candidates to become biomarkers or molecular targets in brain ischemia.
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